Overview
Blood purification firm's preliminary full-year revenue missed analyst expectations
Company's gross margin improved to 72% for full-year 2025
Company scheduled FDA meeting for DrugSorb-ATR submission
Fourth quarter 2025 revenue is expected to be approximately $9.2 million
Outlook
CytoSorbents expects to file De Novo Application for DrugSorb-ATR by Q1 2026
Company anticipates FDA regulatory decision on DrugSorb-ATR by mid-2026
CytoSorbents aims for cash-flow break-even in Q1 2026
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
$37 mln
$39.10 mln (3 Analysts)
FY Product Gross Margin
72.00%
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cytosorbents Corp is $5.38, about 701% above its January 9 closing price of $0.67
Press Release: ID:nPnbl6F7ta
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
